MedWatch

Zealand’s diabetes-hope recommended for approval

The diabetes drug Lyxumia, developed by Danish company Zealand Pharma and pharmaceutical giant Sanofi, has been recommended for approval by the EMA’s medical committee.

Foto: Colourbox

Lyxumia, a GLP-1 analogue used for treating diabetes, has moved one step closer to the European market; the Victoza-rival has been recommended for approval by the CHMP, a medical committee under the European Medicines Agency (EMA).

The decision was announced late last week and covers one daily dose for the treatment of type 2 diabetes in adults. It was later confirmed by Sanofi and Zealand Pharma.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier